학술논문

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Document Type
Article
Author
Verstovsek, SrdanGerds, Aaron TVannucchi, Alessandro MAl-Ali, Haifa KathrinLavie, DavidKuykendall, Andrew TGrosicki, SebastianIurlo, AlessandraGoh, Yeow TeeLazaroiu, Mihaela CEgyed, MiklosFox, Maria LauraMcLornan, DonalPerkins, AndrewYoon, Sung-SooGupta, VikasKiladjian, Jean-JacquesGranacher, NikkiLee, Sung-EunOcroteala, LuminitaPassamonti, FrancescoHarrison, Claire NKlencke, Barbara JRo, SunheeDonahue, RafeKawashima, JunMesa, RubenAbulafia, Adi ShachamAl-Ali, Haifa KathrinAndreasson, BjornAngona, AnnaAyala, RosaBang, Soo-MeeBank, BruceBarraco, FiorenzaBeggiato, EloiseBenghiat, Fleur SamanthaBonifacio, MassimiliaNoBories, ClaireBorsaru, GabrielaBrabrand, MetteBraester, AndreiBroliden, AndesBuxhofer-Ausch, VeronikaCambier, NathalieCaramella, MariannaCarpentier, BenjaminCascavilla, NicolaCastellano, Maria GiraldoChang, HungChen, Chih-ChengCheong, June-WonChoi, YunsukChoi, PhilipCorsetti, Maria TeresaCuadrado, Isabel MonteroCunningham, JuliaDamaj, Gandhi LaurentDe Stefano, ValerioDelage, RobertDelgado, Regina GarcĺaDiaz, Jose Miguel TorregrosaDombi, PéterDubruille, VivianeEgyed, MiklósEl Fassi, DanielElinder-Camburn, AnnaElli, Elena MariaEllis, MartinFava, CarmenFazal, SalmanFleischman, AngelaFoltz, LyndaFox, LauraGabrail, NashatGarcĺa-Gutiérrez, Jose ValentĺnGerds, AaronGirault, StephaneGisslinger, HeinzGluvacov, AlexandruGoh, Yeow TeeGöthert, JoachimGranacher, NikkiGrosicki, SebastianGupta, VikasHadjiev (Hadzhiev), Evgeni (Evgueniy)Hafraoui, KaoutarHamed, AryanHarrison, ClaireHasselbalch, HansHauser, HannsHeaney, MarkHebart, HolgerHernandez Rivas, Jesus MariaHiguero Saavedra, VictorHillis, ChristopherHou, Hsin-AnHow, JonathanHuang, DanielHus, MarekIllés, ArpadIsidori, AlessandroIurlo, AlessandraIvanov, VadimJohansson, PeterJung, Chul WonKiladjian, Jean-JacquesKirgner, IlyaKoren-Michowitz, MayaKoschmieder, SteffenKosztolanyi, Szabolcs OrsKreiniz, NataliaKuykendall, AndrewLambert, JonathanLaribi, KamelLascaux, AxelleLavie, NoaLavie, DavidLazaroiu, MihaelaLeahy, MichaelLech-Maranda, EwaLee, Sung-EunLee, Won SikLegrand, OllivierLemoli, RobertoLiang, JamesLim, Sung-NamLoschi, MichaelLucchesi, AlessandroMacarie, IoanMarolleau, Jean-PierreMartelli, MaurizioMayer, JiriMcCloskey, JamesMcDermott, ChristopherMcLornan, DonalMcMahon, BrandonMehta, PriyankaMesa, RubenMikala, GáborMilojkovic, DraganaMineur, PhilippeMishchenko, ElenaMoon, Joon HoNagy, ZsoltNarayanan, SrinivasanO'Connell, CaseyOcroteala, LuminitaOh, StephenOjeda-Uribe, MarioOng, Kiat HoeOtegbeye, FolashadePalmer, JeannePane, FabrizioPassamonti, FrancescoPatriarca, AndreaPerkins, AndrewPietrantuono, GiuseppePlander, MarkPlatzbecker, UwePrasad, RitamPrejzner, WitoldRachow, TobiasRadinoff, AtanasRejtő, LászlóRinaldi, CiroRobak, TadeuszRodriguez, Maria Angeles FernandezRonson, AaronRoss, DavidSacha, TomaszSadjadian, ParvisSalar, AntonioSantillana, Guillermo SanzScheid, ChristofSchmidt, AlineSeverinsen, Marianne TangStoeva, VeraSzwedyk, PawełTiribelli, MarioTrautmann-Grill, KarolinTrottier, AmyTzvetkov, Nikolayvan Droogenbroeck, JanuszVannucchi, AlessandroVerstovsek, SrdanVianelli, Nicolavon Bubnoff, NikolasWolf, DominikWoszczyk, DariuszWoźny, TomaszWróbel, TomaszXicoy, BlancaYeh, Su-PengYoon, Sung-Soo
Source
The Lancet; January 2023, Vol. 401 Issue: 10373 p269-280, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.